AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
AEON is expected to report earnings to rise 400.00% to -10 cents per share on November 13
Q3'26
Est.
$-0.10
Q2'26
Beat
by $0.63
Q4'25
Missed
by $2.64
Q3'25
Missed
by $0.07
Q2'25
Missed
by $0.29
The last earnings report on August 12 showed earnings per share of -1 cents, beating the estimate of -64 cents. With 32.52K shares outstanding, the current market capitalization sits at 11.98M.